| 11. |
- Johansson, Jan, 1949-, et al.
(författare)
-
Occupational safety in the construction industry
- 2019
-
Ingår i: Work. - : IOS Press. - 1051-9815 .- 1875-9270. ; 64:1, s. 21-32
-
Tidskriftsartikel (refereegranskat)abstract
- BACKGROUNDThe paper is a research review focusing on occupational safety in the construction industry.OBJECTIVEThe purpose is to present research that highlights the areas of occupational safety and risks and to identify areas where research is lacking.METHODS326 articles from scientific journals, mainly covering the construction industry in Europe, Canada, USA, Australia and Japan have been studied. The findings are presented under 11 categories: accident statistics; individual factors; legislation and regulations; ethical considerations; risk management; leadership, management, organization; competence; safety design; cost-benefit calculations; programs and models; and technical solutions.RESULTSThe research is dominated by initiatives from researchers and government authorities, while the construction industry only appears as the object for the research. There is a scarcity of research on integrated systems encompassing subcontractors, as well as a lack of research with sociological perspectives on accidents. Furthermore, only a few studies have applied a gender perspective on safety in construction, i.e. there is a need of further research in this particular area.CONCLUSIONSA range of initiatives have been taken to increase safety in the construction industry and the initiatives are mainly reported to be successful. There are some cultural differences, but basically researchers present similar results regardless of country.
|
|
| 12. |
|
|
| 13. |
- Takman, Johanna, 1992-, et al.
(författare)
-
Biogas för tunga lastbilstransporter : barriärer och möjligheter
- 2018
-
Rapport (övrigt vetenskapligt/konstnärligt)abstract
- I denna rapport presenterar vi en fördjupad studie av vilka barriärer och möjligheter som finns för biogas, och framförallt flytande biogas (LBG), för tunga lastbilar i större skala samt hur barriärerna övervinns och möjligheterna nyttjas. Studien identifierar även viktiga varuägare och andra intressenter i Sverige samt vilka krav och villkor dessa ställer för att våga investera i gastekniken. För att besvara studiens frågeställningar genomfördes en genomgång av litteraturen samt intervjuer och workshops med relevanta aktörer. Resultaten pekar på att biogasen är ett drivmedel som kan bidra till minskade koldioxidutsläpp. Vidare nämns även drivkrafter som energitrygghet och en cirkulär ekonomi. Att det nu har kommit nya tunga LBG-lastbilar på marknaden samt att nya styrmedel trätt i kraft ses också som drivkrafter. Avsaknaden av långsiktiga, stabila styrmedel och regelverk samt höga priser och kostnader för exempelvis produktion, fordon och gas angavs vara de största barriärerna. Ytterligare barriärer är exempelvis att det råder kunskapsbrist inom området samt att dagens förnybara drivmedel konkurrerar med varandra istället för att komplettera varandra.Det behövs en ökad långsiktighet i styrmedel som gynnar de mest hållbara förnybara bränslen som finns idag. Det behövs också att svenska styrmedel harmoniseras med styrmedel inom övriga EU på ett bättre sätt än de som funnits fram till idag. Det behövs även ökade möjligheter till stöd som exempelvis gynnar produktionen av biogas, investeringsstöd till de fordon som bäst gynnar att klimatoch andra miljömål nås, samt stöd som inkluderar andrahandsmarknaden för dessa fordon för att påverka marknaden mot en mer miljömässigt hållbar transportsektor. Det behövs informationsinsatser för att informera om biogas i förhållande till andra drivmedel för tunga lastbilar och information om att, samt var, dagens tankstationer för LBG finns. Även demonstrationsprojekt som visar fordonen ute på vägarna samt bidrar till infrastrukturutvecklingen skulle kunna hjälpa till att sprida kunskap och visa att tekniken fungerar och på så sätt utveckla marknaden för LBG.
|
|
| 14. |
- Aad, G., et al.
(författare)
-
The ATLAS Experiment at the CERN Large Hadron Collider
- 2008
-
Ingår i: Journal of Instrumentation. - 1748-0221. ; 3:S08003
-
Forskningsöversikt (refereegranskat)abstract
- The ATLAS detector as installed in its experimental cavern at point 1 at CERN is described in this paper. A brief overview of the expected performance of the detector when the Large Hadron Collider begins operation is also presented.
|
|
| 15. |
- Abrahamsson, Lena, et al.
(författare)
-
Mining and Sustainable Development : Gender, Diversity and Work Conditions in Mining
- 2014
-
Rapport (övrigt vetenskapligt/konstnärligt)abstract
- Swedish mining companies and surrounding mining communities face many challenges when it comes to social sustainable development. For example, a strong mining workplace culture and community identity can create both strong cohesion but also lead to exclusion of certain groups, rejection of new ideas and reinforce traditional, masculine values. Other challenges include recruitment, as well as health and safety in relation to an increased use of contractors and automation of mining. The social dimension is relatively underdeveloped in studies of sustainable development in general and the mining industry in particular. This report reviews research on social sustainable development and mining with a special focus on (1) diversity of lifestyles, (2) gender, and (3) work conditions. Swedish and international research is reviewed and knowledge gaps are identified. All three areas of research can be regarded as relatively mature and they give important contributions to ourunderstanding of social sustainable development in relation to the mining sector even if they not always explicitly refer to it as such. There is a lack of research that links attitudes, policies and activities within companies to their impact on the wider society, and vice versa. Future research should also include the development of methods and indicators for social sustainability relevant for mining.
|
|
| 16. |
- Adolfsson, Jan, et al.
(författare)
-
Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005 : Data from the national prostate cancer register in Sweden
- 2007
-
Ingår i: Scandinavian Journal of Urology and Nephrology. - Stockholm : Taylor & Francis. - 0036-5599 .- 1651-2065. ; 41:6, s. 456-477
-
Tidskriftsartikel (refereegranskat)abstract
- Objective. The incidence of prostate cancer is rising rapidly in Sweden and there is a need to better understand the pattern of diagnosis, tumor characteristics and treatment. Material and methods. Between 1996 and 2005, all new cases of adenocarcinoma of the prostate gland were intended to be registered in the National Prostate Cancer Register (NPCR). This register contains information on diagnosing unit, date of diagnosis, cause of diagnosis, tumor grade, tumor stage according to the TNM classification in force, serum prostate-specific antigen (PSA) levels at diagnosis and primary treatment given within the first 6 months after diagnosis. Results. In total, 72 028 patients were registered, comprising >97% of all pertinent incident cases of prostate cancer in the Swedish Cancer Register (SCR). During the study period there was a considerable decrease in median age at the time of diagnosis, a stage migration towards smaller tumors, a decrease in median serum PSA values at diagnosis, a decrease in the age-standardized incidence rate of men diagnosed with distant metastases or with a PSA level of >100 ng/ml at diagnosis and an increase in the proportion of tumors with Gleason score ≤6. Relatively large geographical differences in the median age at diagnosis and the age-standardized incidence of cases with category T1c tumors were observed. Treatment with curative intent increased dramatically and treatment patterns varied according to geographical region. In men with localized tumors and a PSA level of <20 ng/ml at diagnosis, expectant treatment was more commonly used in those aged ≥75 years than in those aged <75 years. Also, the pattern of endocrine treatment varied in different parts of Sweden. Conclusions. All changes in the register seen over time are consistent with increased diagnostic activity, especially PSA testing, resulting in an increased number of cases with early disease, predominantly tumors in category T1c. The patterns of diagnosis and treatment of prostate cancer vary considerably in different parts of Sweden. The NPCR continues to be an important source for research, epidemiological surveillance of the incidence, diagnosis and treatment of prostate cancer
|
|
| 17. |
- Adolfsson, Jan, et al.
(författare)
-
Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005
- 2007
-
Ingår i: Scandinavian Journal of Urology and Nephrology. - : Informa UK Limited. - 0036-5599 .- 1651-2065. ; 41:6, s. 456-477
-
Tidskriftsartikel (refereegranskat)abstract
- OBJECTIVE: The incidence of prostate cancer is rising rapidly in Sweden and there is a need to better understand the pattern of diagnosis, tumor characteristics and treatment. MATERIAL AND METHODS: Between 1996 and 2005, all new cases of adenocarcinoma of the prostate gland were intended to be registered in the National Prostate Cancer Register (NPCR). This register contains information on diagnosing unit, date of diagnosis, cause of diagnosis, tumor grade, tumor stage according to the TNM classification in force, serum prostate-specific antigen (PSA) levels at diagnosis and primary treatment given within the first 6 months after diagnosis. RESULTS: In total, 72,028 patients were registered, comprising >97% of all pertinent incident cases of prostate cancer in the Swedish Cancer Register (SCR). During the study period there was a considerable decrease in median age at the time of diagnosis, a stage migration towards smaller tumors, a decrease in median serum PSA values at diagnosis, a decrease in the age-standardized incidence rate of men diagnosed with distant metastases or with a PSA level of > 100 ng/ml at diagnosis and an increase in the proportion of tumors with Gleason score <6. Relatively large geographical differences in the median age at diagnosis and the age-standardized incidence of cases with category T1c tumors were observed. Treatment with curative intent increased dramatically and treatment patterns varied according to geographical region. In men with localized tumors and a PSA level of <20 ng/ml at diagnosis, expectant treatment was more commonly used in those aged > or =75 years than in those aged <75 years. Also, the pattern of endocrine treatment varied in different parts of Sweden. CONCLUSIONS: All changes in the register seen over time are consistent with increased diagnostic activity, especially PSA testing, resulting in an increased number of cases with early disease, predominantly tumors in category T1c. The patterns of diagnosis and treatment of prostate cancer vary considerably in different parts of Sweden. The NPCR continues to be an important source for research, epidemiological surveillance of the incidence, diagnosis and treatment of prostate cancer.
|
|
| 18. |
- Asghar, Naveed, 1983-, et al.
(författare)
-
DNA launched suicidal flaviviruses as therapeutic vaccine candidates
- 2018
-
Konferensbidrag (refereegranskat)abstract
- Chronic liver disease, resulting from Hepatitis B virus (HBV), Hepatitis D virus (HDV), or Hepatitis C virus (HCV) infections, contributes to a major health burden worldwide. The relativelyhigh cost of the HCV treatment brings concerns about the accessibility, especially in the developing countries. Hence, there exists a need for cost effect interventions with high efficiency. We aim to develop therapeutic vaccine candidates against HBV, HCV and HDV using DNA based subgenomic flavivirus replicons as a delivery system. Tick-borne encephalitis virus (TBEV), Langat virus (LGTV), West-Nile virus (WNV), or Kunjinvirus (KUNV) replicon with firefly luciferase geneas a reporter were expressed and characterized in cell culture studies. WNV and KUNV replicons showed significantly higher replication compared to their respective negative controls with unfunctional viral RNA dependent RNA polymerase. KUNV and WNV replicons were chosen for cloning the HCV or HB/DV vaccine candidate gene by replacing luciferasegene. Owing to the self-replicating trait of the flavivirus subgenomic replicons, Western blotting demonstrated that the antigen expression by KUNV and WNV replicons was several folds higher than the positive control. These results suggest that DNA based KUNV and WNV replicons may function as carriers for the hepatitis vaccine candidate genes, and these replicons are currently used for in vivostudies in animal models.
|
|
| 19. |
- Asghar, Naveed, 1983-, et al.
(författare)
-
Flavivirus replicon-based novel vaccine candidates against Hepatitis viruses
- 2024
-
Konferensbidrag (refereegranskat)abstract
- Chronic liver disease, resulting from Hepatitis B virus (HBV), Hepatitis D virus (HDV), or Hepatitis C virus (HCV) infections, contributes to a major health burden worldwide. Chronic infections with the hepatitis C virus (HCV) can be effectively cured by antivirals. However, the cured patients can be re-infected as they lack protective immune responses. In addition, the relatively high cost of the HCV treatment brings concerns about the accessibility, especially in the developing countries. Hence, there exists a need for cost effect vaccines with high efficiency to control and possibly eradicate Hepatitis viruses globally. The vaccine should induce either, or both, neutralizing antibodies and protective T cell responses. We have developed and utilized flavivirus replicons as delivery system to prime hepatitis-specific T cell responses. We generated subgenomic replicons of Tick-borne encephalitis virus (TBEV), Langat virus (LGTV), West-Nile virus (WNV), and Kunjin virus (KUNV) expressing either a fusion protein between the HCV NS3/4A and a stork hepatitis B virus core or a vaccine candidate gene of HB/DV. Transfection experiments showed that the antigen expression by KUNV and WNV replicons was several folds higher than the antigen expression of control DNA plasmid with CMV promoter. The immunogenicity of these flavivirus replicons was evaluated in mice. The KUNV replicon triggered a potent cellular immune response with respect to priming of HCV NS3/4A-specific T cells as determined by ELISpot, and polyfunctionality. In short, the newly developed KUNV replicon- based vaccine is an attractive candidate to provide protection against hepatitis viruses.
|
|
| 20. |
- Asghar, Naveed, 1983-, et al.
(författare)
-
Immunogenicity of DNA launched suicidal flavivirus replicons for protective vaccination against hepatitis viruses
- 2019
-
Konferensbidrag (refereegranskat)abstract
- Chronic liver disease, resulting from Hepatitis B virus (HBV), Hepatitis D virus (HDV), or Hepatitis C virus (HCV) infections, contributes to a major health burden worldwide. Chronic infections with the hepatitis C virus (HCV) can be effectively cured by antivirals. However, as cured patients can be re-infected they lack protective immune responses. In addition, the relativelyhigh cost of the HCV treatment brings concerns about the accessibility, especially in the developing countries. Hence, there exists a need for cost effect vaccines with high efficiency to control and possibly eradicate Hepatitis viruses globally. The vaccine should induce either, or both, neutralizing antibodies and protective T cell responses. We therefore have developed DNA based flavivirus replicons as a potent delivery system that effectively prime HCV-specific T cell responses. We generated suicidal subgenomic DNA replicons of Tick-borne encephalitis virus (TBEV), Langat virus (LGTV), West-Nile virus (WNV), and Kunjinvirus (KUNV) expressing either a fusion protein between the HCV NS3/4A and a stork hepatitis B virus core or a vaccine candidate gene of HB/DV. Transfection experiments showed that the antigen expression by KUNV and WNV replicons was several folds higher than the antigen expression by standard DNA plasmid with CMV promoter. The immunogenicity of three suicidal flaviviral DNA replicons expressing HCV NS3/4A was tested in mice and compared to HCV NS3/4A expression by the standard DNA plasmid. The KUNV-HCV replicon was the best replicon-based immunogen with respect to priming of HCV NS3/4A-specific T cells as determined by ELISpot, dextramer staining, and polyfunctionality. Importantly, a mutant KUNV-HCV immunogen lacking replication failed to induce immune responses. Thus, the newly developed KUNV-based suicidal DNA launched replicon vaccine for HCV is a highly attractive candidate as a prophylactic vaccine against chronic hepatitis C. In addition, we are currently testing the immunogenicity of KUNV-HB/DV replicon in mice.
|
|
